HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: CBD In Europe – The State Of Play Today

Executive Summary

HBW Insight editors David Ridley and Tom Gallen discuss the current state of play concerning cannabidiol dietary supplements regulation in Europe, and find out what consumer health companies need to know according to CBD expert Greer Deal from Global Regulatory Service. 

HBW Insight's David Ridley (Senior Editor, EU) and Tom Gallen (Managing Editor, EU) discuss the current situation with cannabidiol dietary supplements in Europe, covering the latest moves by the European Commission to classify CBD as a narcotic, as well as the way that individual member states Germany and France have approached the regulation of this popular ingredient.
 
We also get the lowdown from CBD expert Greer Deal, director, Global Regulatory Services, on what the key considerations are for consumer health companies either already operating in this exciting space, or are thinking about entering the European CBD market.

 

 

Related Content

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel